Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.

Devarakonda S, Sankararaman S, Herzog BH, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D.

Clin Cancer Res. 2019 Oct 15;25(20):6119-6126. doi: 10.1158/1078-0432.CCR-19-0879. Epub 2019 Jul 12.

PMID:
31300452
2.

Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.

Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano JA, Mell LK, Cohen EEW, Sharabi AB.

Clin Cancer Res. 2019 Jul 15;25(14):4211-4223. doi: 10.1158/1078-0432.CCR-18-0871. Epub 2019 Feb 27. Review.

PMID:
30814108
3.

Immunotherapeutic Approaches to the Management of Head and Neck Cancer.

Nan X, Gold KA, Cohen E.

Oncology (Williston Park). 2018 Dec 17;32(12):617-9, 625-6.

4.

Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.

Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V.

Ann Oncol. 2019 Mar 1;30(3):471-477. doi: 10.1093/annonc/mdy549.

PMID:
30596812
5.

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.

Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN.

J Clin Oncol. 2018 Sep 10;36(26):2693-2701. doi: 10.1200/JCO.2017.77.5841. Epub 2018 May 16.

PMID:
29768119
6.

Hemostatic and Absorbent PolyHIPE-Kaolin Composites for 3D Printable Wound Dressing Materials.

Streifel BC, Lundin JG, Sanders AM, Gold KA, Wilems TS, Williams SJ, Cosgriff-Hernandez E, Wynne JH.

Macromol Biosci. 2018 May;18(5):e1700414. doi: 10.1002/mabi.201700414. Epub 2018 Apr 17.

PMID:
29665285
7.

Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.

Gold KA, Kies MS, William WN Jr, Johnson FM, Lee JJ, Glisson BS.

Cancer. 2018 May 15;124(10):2169-2173. doi: 10.1002/cncr.31346. Epub 2018 Mar 26.

8.

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.

Cascone T, Gold KA, Swisher SG, Liu DD, Fossella FV, Sepesi B, Pataer A, Weissferdt A, Kalhor N, Vaporciyan AA, Hofstetter WL, Wistuba II, Heymach JV, Kim ES, William WN Jr.

Ann Thorac Surg. 2018 Feb;105(2):418-424. doi: 10.1016/j.athoracsur.2017.08.052. Epub 2017 Dec 6.

9.

Nanoengineered Colloidal Inks for 3D Bioprinting.

Peak CW, Stein J, Gold KA, Gaharwar AK.

Langmuir. 2018 Jan 23;34(3):917-925. doi: 10.1021/acs.langmuir.7b02540. Epub 2017 Oct 25.

PMID:
28981287
10.

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial.

Thress KS, Jacobs V, Angell HK, Yang JC, Sequist LV, Blackhall F, Su WC, Schuler M, Wolf J, Gold KA, Cantarini M, Barrett JC, Jänne PA.

J Thorac Oncol. 2017 Oct;12(10):1588-1594. doi: 10.1016/j.jtho.2017.07.011. Epub 2017 Jul 24.

11.

The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer.

Sepesi B, Gold KA, Correa AM, Heymach JV, Vaporciyan AA, Roszik J, Dmitrovsky E, Liu X.

J Thorac Oncol. 2017 Aug;12(8):1280-1287. doi: 10.1016/j.jtho.2017.05.010. Epub 2017 May 25.

12.

Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers.

Cox VL, Bhosale P, Varadhachary GR, Wagner-Bartak N, Glitza IC, Gold KA, Atkins JT, Soliman PT, Hong DS, Qayyum A.

Radiology. 2017 May;283(2):314-340. doi: 10.1148/radiol.2017152224. Review.

PMID:
28418819
13.

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR.

Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8.

PMID:
27836716
14.

Sleep and Breathing … and Cancer?

Owens RL, Gold KA, Gozal D, Peppard PE, Jun JC, Dannenberg AJ, Lippman SM, Malhotra A; UCSD Sleep and Cancer Symposium Group.

Cancer Prev Res (Phila). 2016 Nov;9(11):821-827. Epub 2016 Sep 7. Review. Erratum in: Cancer Prev Res (Phila). 2017 Jan;10 (1):98.

15.

The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL.

Ungewiss C, Rizvi ZH, Roybal JD, Peng DH, Gold KA, Shin DH, Creighton CJ, Gibbons DL.

Sci Rep. 2016 Jan 5;6:18652. doi: 10.1038/srep18652.

16.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SI; study investigators.

Lancet Oncol. 2016 Feb;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19. Erratum in: Lancet Oncol. 2017 Mar;18(3):e134.

17.

New strategies in immunotherapy for non-small cell lung cancer.

Carrizosa DR, Gold KA.

Transl Lung Cancer Res. 2015 Oct;4(5):553-9. doi: 10.3978/j.issn.2218-6751.2015.06.05. Review.

18.

Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer.

Nien HH, Sturgis EM, Kies MS, El-Naggar AK, Morrison WH, Beadle BM, Johnson FM, Gunn GB, Fuller CD, Phan J, Gold KA, Frank SJ, Skinner H, Rosenthal DI, Garden AS.

Head Neck. 2016 Apr;38 Suppl 1:E1554-61. doi: 10.1002/hed.24278. Epub 2015 Nov 23.

PMID:
26595157
19.

Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma.

Xing Y, Zhang J, Lin H, Gold KA, Sturgis EM, Garden AS, Lee JJ, William WN Jr.

Cancer. 2016 Feb 15;122(4):534-45. doi: 10.1002/cncr.29780. Epub 2015 Nov 10.

20.

Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation.

Shoultz-Henley S, Garden AS, Mohamed AS, Sheu T, Kroll MH, Rosenthal DI, Gunn GB, Hayes AJ, French C, Eichelberger H, Kalpathy-Cramer J, Smith BD, Phan J, Ayoub Z, Lai SY, Pham B, Kies M, Gold KA, Sturgis E, Fuller CD.

Int J Cancer. 2016 Mar 1;138(5):1290-7. doi: 10.1002/ijc.29870. Epub 2015 Oct 9.

21.

FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-Small-Cell Lung Cancer.

Gold KA, Erasmus JJ.

J Thorac Oncol. 2015 Aug;10(8):1131-2. doi: 10.1097/JTO.0000000000000599. No abstract available.

22.

The Myb-p300 Interaction Is a Novel Molecular Pharmacologic Target.

Liu X, Gold KA, Dmitrovsky E.

Mol Cancer Ther. 2015 Jun;14(6):1273-5. doi: 10.1158/1535-7163.MCT-15-0271. Epub 2015 May 20. No abstract available.

23.

Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy.

Takiar V, Ma D, Garden AS, Li J, Rosenthal DI, Beadle BM, Frank SJ, Fuller CD, Gunn GB, Morrison WH, Hutcheson K, El-Naggar AK, Gold KA, Kupferman ME, Phan J.

Head Neck. 2016 Apr;38 Suppl 1:E925-33. doi: 10.1002/hed.24128. Epub 2015 Jul 18.

PMID:
25994561
24.

Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry.

Zhang J, Gold KA, Lin HY, Swisher SG, Xing Y, Lee JJ, Kim ES, William WN Jr.

J Thorac Oncol. 2015 Apr;10(4):682-90. doi: 10.1097/JTO.0000000000000456.

25.

ROS1--targeting the one percent in lung cancer.

Gold KA.

N Engl J Med. 2014 Nov 20;371(21):2030-1. doi: 10.1056/NEJMe1411319. No abstract available.

PMID:
25409376
26.

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA.

Science. 2014 Oct 10;346(6206):256-9. doi: 10.1126/science.1256930.

27.

Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.

Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B.

J Natl Cancer Inst. 2014 Sep 10;106(9). pii: dju204. doi: 10.1093/jnci/dju204. Print 2014 Sep.

28.

A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.

Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM.

Oncologist. 2014 Oct;19(10):1040-1. doi: 10.1634/theoncologist.2014-0228. Epub 2014 Aug 28.

29.

Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy.

Gold KA, Kim ES, Liu DD, Yuan P, Behrens C, Solis LM, Kadara H, Rice DC, Wistuba II, Swisher SG, Hofstetter WL, Lee JJ, Hong WK.

Clin Cancer Res. 2014 Apr 1;20(7):1946-54. doi: 10.1158/1078-0432.CCR-13-1959. Epub 2013 Dec 23.

30.

Afatinib in the treatment of head and neck squamous cell carcinoma.

Ferrarotto R, Gold KA.

Expert Opin Investig Drugs. 2014 Jan;23(1):135-43. doi: 10.1517/13543784.2014.858696. Epub 2013 Nov 25. Review.

PMID:
24266694
31.

Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database.

Wang H, Liao Z, Zhuang Y, Xu T, Nguyen QN, Levy LB, O'Reilly M, Gold KA, Gomez DR.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1071-7. doi: 10.1016/j.ijrobp.2013.08.033. Epub 2013 Oct 22.

32.

Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: use it or lose it.

Hutcheson KA, Bhayani MK, Beadle BM, Gold KA, Shinn EH, Lai SY, Lewin J.

JAMA Otolaryngol Head Neck Surg. 2013 Nov;139(11):1127-34. doi: 10.1001/jamaoto.2013.4715.

33.

The role of systemic treatment before, during, and after definitive treatment.

Gold KA, Neskey M, William WN Jr.

Otolaryngol Clin North Am. 2013 Aug;46(4):645-56. doi: 10.1016/j.otc.2013.04.005. Epub 2013 May 25. Review.

34.

Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.

William WN Jr, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ; University of Texas M.D. Anderson Lung Cancer Collaborative Research Group.

J Thorac Oncol. 2013 Feb;8(2):222-8. doi: 10.1097/JTO.0b013e3182774108.

35.

Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling.

Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, Chu Z, Garcia M, Kabbout M, Fan YH, Behrens C, Liu DA, Mao L, Lee JJ, Gold KA, Wang J, Coombes KR, Kim ES, Hong WK, Wistuba II.

Cancer Prev Res (Phila). 2013 Jan;6(1):8-17. doi: 10.1158/1940-6207.CAPR-12-0290. Epub 2012 Oct 19.

36.

Natural-agent mechanisms and early-phase clinical development.

Wang JL, Gold KA, Lippman SM.

Top Curr Chem. 2013;329:241-52. doi: 10.1007/128_2012_341. Review.

PMID:
22851156
37.

Personalizing lung cancer prevention through a reverse migration strategy.

Gold KA, Kim ES, Wistuba II, Hong WK.

Top Curr Chem. 2013;329:221-40. doi: 10.1007/128_2012_338. Review.

38.

Sorafenib in non-small cell lung cancer.

Zhang J, Gold KA, Kim E.

Expert Opin Investig Drugs. 2012 Sep;21(9):1417-26. doi: 10.1517/13543784.2012.699039. Epub 2012 Jun 24. Review.

PMID:
22725255
39.

New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy.

Gold KA, Wistuba II, Kim ES.

Clin Cancer Res. 2012 Jun 1;18(11):3002-7. doi: 10.1158/1078-0432.CCR-11-2055. Epub 2012 Mar 29. Erratum in: Clin Cancer Res. 2012 Aug 1;18(15):4215.

40.

The BATTLE to personalize lung cancer prevention through reverse migration.

Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK.

Cancer Prev Res (Phila). 2011 Jul;4(7):962-72. doi: 10.1158/1940-6207.CAPR-11-0232.

41.

Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model.

Lee J, Ryu SH, Kang SM, Chung WC, Gold KA, Kim ES, Hittelman WN, Ki Hong W, Koo JS.

Cancer Prev Res (Phila). 2011 Aug;4(8):1306-15. doi: 10.1158/1940-6207.CAPR-10-0364. Epub 2011 Apr 19.

42.

Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.

William WN Jr, Gold KA, Kim ES.

Ann Oncol. 2009 Sep;20(9):1455-7. doi: 10.1093/annonc/mdp387. No abstract available.

PMID:
19704160
43.

Role of molecular markers and gene profiling in head and neck cancers.

Gold KA, Kim ES.

Curr Opin Oncol. 2009 May;21(3):206-11. doi: 10.1097/CCO.0b013e328329ac00. Review.

PMID:
19346943
44.

Targeted therapies in squamous cell carcinoma of the head and neck.

Gold KA, Lee HY, Kim ES.

Cancer. 2009 Mar 1;115(5):922-35. doi: 10.1002/cncr.24123. Review.

45.

Probing the building blocks of eumelanins using scanning electron microscopy.

Nofsinger JB, Forest SE, Eibest LM, Gold KA, Simon JD.

Pigment Cell Res. 2000 Jun;13(3):179-84.

PMID:
10885677
46.

Long-term follow-up after coronary artery bypass.

Hall RJ, Garcia E, Mathur VS, Busch U, Cooley DA, Gold KA, Gray AG.

Cleve Clin Q. 1978 Spring;45(1):162-5. No abstract available.

PMID:
306302

Supplemental Content

Support Center